In a phase 3 trial, OCA improved liver fibrosis while NASH resolution did not reach statistical significance in an 18-month interim analysis 60 .
← all excerpts
Modelling human liver fibrosis in the context of non-alcoholic steatohepatitis using a microphysiological system.
1
—
—